MyDekla (Daclatasvir), an NS5A replication complex inhibitor, is the first 12-week, all-oral therapy indicated for use with Sofosbuvir, for the treatment of hepatitis C (HCV) genotype 3 infections. The drug was manufactured by MyLan Pharmaceuticals.
Daclatasvir belongs to a class of new directly acting antivirals that inhibit non-structural protein NS5A, inhibiting hepatitis C virus RNA replication. Daclatasvir has inhibitory activity against hepatitis C virus, with broad genotypic coverage and a pharmacokinetic profile that supports once-daily dosing.
MyDekla in people with cirrhosis:
HCV treatment guidelines recommend that people with serious liver damage (Child-Pugh Class B or C cirrhosis) be treated by a specialist. MyDekla can be used in mild, moderate, or severe hepatic impairment without dose adjustment. In clinical trials, people with Child-Pugh Class B or Class C cirrhosis have been treated with MyDekla (Daclatasvir) and Sofosbuvir (Hepcinat), with or without RBV.
MyDekla (in combination with other medicines) works by stopping the HCV from multiplying and infecting liver cells. After you stop taking MyDekla, your doctor will monitor your blood for HCV. If HCV is still not detected in your blood at least 12 weeks after stopping treatment, you have what is called a sustained virologic response (SVR), also referred to as virologic cure.
The safety and efficacy of Daclatasvir in children aged below 18 years have not yet been established.
Ask your doctor if you have any questions about why MyDekla has been prescribed for you.